Keywords: Fluorodeoxyglucose F18, Neoplasms, Therapy, Positron Emission Tomography, Cetuximab, Cisplatin, Fluorodeoxyglucose F 18, Fluorouracil, Folinic Acid, Irinotecan, Diagnostic Agent, Brain Tumor, Breast Cancer, Cancer Chemotherapy, Cancer Radiotherapy, Clinical Assessment, Colorectal Cancer, Computer Assisted Tomography, Diagnostic Procedure, Esophagus Cancer, Head And Neck Carcinoma, Human, Lung Non Small Cell Cancer, Monitoring, Outcome Assessment, Quantitative Analysis, Review, Stomach Cancer, Tissue Characterization, Treatment Response, Metabolism, Methodology, Treatment Outcome, Positron-Emission Tomography, X-Ray Computed,
Affiliations: *** IBB - CNR ***
IRCCS, CROB, Rionero in Vulture, Potenza, Italy
SDN Foundation, Institute of Diagnostic and Nuclear Development, Naples, Italy
Department of Biomorphological and Functional Sciences, University Federico II, Naples, Italy
References: Not available.
[18F]FDG-PET-CT for early monitoring of tumor response: When and why
18F-fluorodeoxyglucose positron emission tomography ([ 18F]FDG PET) has been recognized as a suitable tool in tumor response assessment of patients complaining with solid tumors who have undergone chemo- and radiotherapy. It offers the advantage of functional tissue characterization, which is independent from morphologic criteria allowing to differentiate disease relapse from therapy-induced fibrosis. At present, there is a growing body of evidence that PET semi-quantitative assessment of treatment-induced changes in tumor [18F]FDG avidity may predict early tumor response and patient outcome. Patient management might be changed. For instance, in non responder patients this novel diagnostic approach would hamper useless "wait and watch" attitude in implementing further options or identifying those needing additional therapeutic strategies. On the other hand, for those patients revealing promptly a favourable metabolic response a cost-sparing approach could be implemented avoiding expensive diagnostic procedures during the follow-up as well as the risk of over-treating. In any case, since even a partial metabolic response may be an indication for continuing therapy, the advantage of metabolic assessment over conventional procedures may be clinically relevant. Although a morphological assessment has been considered for long time the standard for detecting therapy response, limitations of conventional computed tomography-based evaluation in solid tumors are well-known. PET provides an independent means of assessing malignancy. However, no consensus has been achieved until now regarding the optimal timing in performing PET during or at completion of treatment.
[18F]FDG-PET-CT for early monitoring of tumor response: When and why
Bruni AC, Bernardi L, Colao R, Rubino E, Smirne N, Frangipane F, Terni B, Curcio SA, Mirabelli M, Clodomiro A, Di Lorenzo R, Maletta R, Anfossi M, Gallo M, Geracitano S, Tomaino C, Muraca MG, Leotta A, Lio SG, Pinessi L, Rainero I, Sorbi S, Nee L, Milan G, Pappata S, Postiglione A, Abbamondi N, Forloni G, St George Hyslop P, Rogaeva E, Bugiani O, Giaccone G, Foncin JF, Spillantini MG, Puccio G * Worldwide distribution of PSEN1 Met146Leu mutation: A large variability for a founder mutation(1597 views) Neurology (ISSN: 0028-3878, 1526-632x, 1526-632xelectronic), 2010 Mar 9; 74(10): 798-806. Impact Factor:8.017 ViewExport to BibTeXExport to EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(1039 views) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 ViewExport to BibTeXExport to EndNote